Add to Your Calendar
As TriPaw expands its pharmaceuticals and product offerings, it faces potential enforcement risks ranging from DEA audits to FDA warning letters and consumer class actions. This session will examine recent enforcement trends related to TriPaw’s business operations—including the possible novel use of the False Claims Act in animal health cases—and share strategies for compliance, internal investigations, and defense. The discussion will focus on how to build resilient programs that safeguard innovation while minimizing enforcement exposure.